Results 61 to 70 of about 1,030 (166)

Topical Calcineurin Inhibitors and Lymphoma Risk: Evidence Update with Implications for Daily Practice [PDF]

open access: yes, 2013
Topical calcineurin inhibitors (TCIs), commercially available since 2000–2001, are the first and only topical medications approved for chronic treatment of atopic dermatitis (AD) in pediatric patients and remain a welcomed alternative to topical ...
Adelaide A. Hebert   +2 more
core   +1 more source

The use ofnatural substances in thetreatment of rhinosinusitis in thelight of the EuropeanPosition Paper on Rhinosinusitis and Nasal Polyps 2012

open access: yesPediatria i Medycyna Rodzinna, 2014
Rhinosinusitis is a very common condition of the upper respiratory tract. The disease may be caused by viral, bacterial or fungal infections as well as by allergens or air pollution (e.g. tobacco smoke), with viral infections being the most common cause.
Małgorzata Pachecka   +2 more
doaj   +1 more source

Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. [PDF]

open access: yes, 2014
BACKGROUND: Pharmacological therapy for chronic obstructive pulmonary disease (COPD) is aimed at relieving symptoms, improving quality of life and preventing or treating exacerbations.Treatment tends to begin with one inhaler, and additional therapies ...
Aalbers   +511 more
core   +1 more source

Suppression of cytokine release by fluticasone furoate vs. mometasone furoate in human nasal tissue ex-vivo.

open access: yesPLoS ONE, 2014
BackgroundTopical glucocorticosteroids are the first line therapy for airway inflammation. Modern compounds with higher efficacy have been developed, but head-to-head comparison studies are sparse.ObjectiveTo compare the activity of two intranasal ...
Nan Zhang   +7 more
doaj   +1 more source

The use of intranasal glucocorticosteroids in the treatment of rhinosinusitis: Focus on mometasone furoate [Intranazal'nye glyukokortikosteroidy v terapii rinosinusita: fokus na mometazona furoat]

open access: yes, 2020
В статье обсуждается механизм действия, эффективность и безопасность интраназальных глюкокортикостероидов (инГКС) при остром, рецидивирующем и хроническом риносинусите (РС). В последней версии Европейских рекомендаций инГКС присвоен высший уровень доказательств — Ia и высшая сила рекомендаций — А при остром РС и полипозном РС.
Ushkalova E.A.   +2 more
openaire   +2 more sources

Intranasal Treatment of Acute Rhinosinusitis - Recommendations, Efficacy and Safety [PDF]

open access: yes, 2023
Introduction and purpose: Acute rhinosinusitis is a common condition worldwide, usually caused by respiratory viruses. Nasal epithelium is their primary point of entry and an active responder to the infection.
Abod, Leila   +4 more
core   +1 more source

Glucocorticosteroid-induced spinal osteoporosis: scientific update on pathophysiology and treatment [PDF]

open access: yes, 2018
Glucocorticosteroid-induced osteoporosis (GIOP) is the most frequent of all secondary types of osteoporosis. The understanding of the pathophysiology of glucocorticoid (GC) induced bone loss is of crucial importance for appropriate treatment and ...
Buergi, Elizabeth   +4 more
core  

Haemophilus Influenzae Responds to Glucocorticoids Used in Asthma Therapy by Modulation of Biofilm Formation and Antibiotic Resistance [PDF]

open access: yes, 2015
Glucocorticosteroids are used as a main treatment to reduce airway inflammation in people with asthma who suffer from neutrophilic airway inflammation, a condition frequently associ- ated with Haemophilus influenzae colonization.
An, Shi-qi   +10 more
core   +1 more source

The treatment of drug-induced rhinitis with an original intranasal combination: Efficacy and safety in experimental animals

open access: yesФармация и фармакология (Пятигорск)
Rhinitis medicamentosa (RM) is a common complication of prolonged use of nasal decongestants, leading to structural changes in the nasal mucosa. Despite the effectiveness of intranasal glucocorticosteroids, their use may be accompanied by side effects ...
E. A. Smolyarchuk   +9 more
doaj   +1 more source

Overview of Newer Glucocorticosteroid Preparations for Inflammatory Bowel Disease [PDF]

open access: yes, 1990
Because the glucocorticosteroid receptor seems to be uniform in the human body, there is currently no support for a possibility of separating the therapeutic and adverse glucocorticosteroid actions at the receptor level.
R Brattsand
core   +2 more sources

Home - About - Disclaimer - Privacy